These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33692294)

  • 1. Neoadjuvant Endocrine Therapy for Operable Breast Cancer: A Retrospective Analysis of Real-World Use.
    Iwamoto M; Takei H; Ninomiya J; Asakawa H; Kurita T; Yanagihara K; Iida S; Sakatani T; Ohashi R
    J Nippon Med Sch; 2021 Nov; 88(5):448-460. PubMed ID: 33692294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-Year Neoadjuvant Endocrine Therapy in Breast Cancer.
    Rusz O; Vörös A; Varga Z; Kelemen G; Uhercsák G; Nikolényi A; Ormándi K; Simonka Z; Kahán Z
    Pathol Oncol Res; 2015 Sep; 21(4):977-84. PubMed ID: 25753983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era.
    Nye L; Rademaker A; Gradishar WJ
    Clin Breast Cancer; 2017 Jul; 17(4):e185-e189. PubMed ID: 28185739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
    Grassadonia A; Di Nicola M; Grossi S; Noccioli P; Tavoletta S; Politi R; Angelucci D; Marinelli C; Zilli M; Ausili Cefaro G; Tinari N; De Tursi M; Iezzi L; Cioffi P; Iacobelli S; Natoli C; Cianchetti E
    Ann Surg Oncol; 2014 May; 21(5):1575-82. PubMed ID: 24522992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy.
    Ju NR; Jeffe DB; Keune J; Aft R
    Breast Cancer Res Treat; 2013 Jan; 137(1):195-201. PubMed ID: 23149464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study.
    Ferreira AR; Ribeiro J; Miranda A; Mayer A; Passos-Coelho JL; Brito M; Fernandes J; Gouveia J; Costa L; Vaz-Luis I
    Clin Breast Cancer; 2019 Oct; 19(5):e654-e667. PubMed ID: 31327728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM; Harhay MO; Zhang P; Ugras S
    Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
    Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
    Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.
    Fisher CS; Ma CX; Gillanders WE; Aft RL; Eberlein TJ; Gao F; Margenthaler JA
    Ann Surg Oncol; 2012 Jan; 19(1):253-8. PubMed ID: 21725686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD; Nassar A; Siddiqui MT; Cohen C
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
    Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
    Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Rossi L; Verrico M; Tomao S; Ricci F; Fontana A; Spinelli GP; Colonna M; Vici P; Tomao F
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):105-111. PubMed ID: 31754747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
    Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
    Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
    Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
    Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
    Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
    Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.